Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Status unknown · Phase 3 · NCT05799248
Conditions: Prostate Cancer
At a glance
- Research payments reported, 2025
- $45,592
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 113
About the trial
- Sponsor
- MidLantic Urology (with Blue Earth Diagnostics)
- Tested
- rhPSMA-7.3 (18F) (drug)
- Dates
- Started 2023-04-27; completion 2024-05-28
- Results posted
- Not yet
Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b Sponsor: MidLantic Urology Funding Organization: Blue Earth Diagnostics Ltd Study Design: This is a Phase 3b, multi-center, single-arm, diagnostic imaging study designed to detect metastatic lesions in men diagnosed with high-risk prostate cancer.
From ClinicalTrials.gov, last updated 2024-05-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $45,592 in research payments for this study in 2025 (9 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Midlantic Urology $45,592
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.